

DCAT
TOP ↑
Industry
NEWS

***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*



1. [Sanofi Ups Bid for Medivation; Enters Confidentiality Agreement](#)

In its ongoing effort to acquire Medivation, a San Francisco-based biopharmaceutical company, Sanofi has upped its bid from approximately \$9.3 billion to \$10 billion and has entered into an agreement under which Sanofi will be provided due diligence access and confidential information. Sanofi is one of several companies interested in acquiring the company. [Read More](#)

2. [AstraZeneca, LEO Pharma Sign Potential \\$1 Billion Licensing Deal](#)

AstraZeneca has entered into agreements with LEO Pharma A/S for the global license to tralokinumab, an investigational anti-IL-13 monoclonal antibody for treating atopic dermatitis, an inflammatory skin disease. LEO Pharma will make an upfront payment to AstraZeneca of \$115 million for the exclusive, global rights to tralokinumab in atopic dermatitis and any future additional dermatology indications. LEO Pharma will also pay AstraZeneca up to \$1 billion in commercially related milestones and up to mid-teen tiered percentage royalties on product sales. AstraZeneca will manufacture and supply tralokinumab to LEO Pharma. [Read More](#)

3. [BMS Acquires Swedish Pharma Company Cormorant](#)

Bristol-Myers Squibb (BMS) has acquired Cormorant, a privately held Stockholm, Sweden-based pharmaceutical company developing therapies for cancer and rare diseases. The acquisition gives BMS full rights to Cormorant's HuMax-IL8 antibody program and the lead candidate HuMax-IL8, a Phase I/II monoclonal antibody targeted against interleukin-8 that represents a potentially complementary immuno-oncology mechanism of action to T-cell directed antibodies and co-stimulatory molecules. [Read More](#)

4. [Merck & Co. To Acquire Brazilian Animal Health Company for \\$400 Million](#)

Merck Animal Health, the animal business of Merck & Co., has agreed to acquire a controlling interest in Vallée S.A., a privately held producer of animal health products in Brazil for approximately \$400 million. Vallée has a portfolio of more than 100 products spanning parasiticides, anti-infectives, and vaccines. [Read More](#)

5. [Takeda, TiGenix Sign \\$400-Million Plus Deal For Crohn's Disease Drug](#)

Takeda Pharmaceutical Company and TiGenix NV, a Belgian biopharmaceutical company, have entered into an exclusive ex-US license, development, and commercialization agreement for Cx601, a suspension of allogeneic adipose-derived stem cells injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn's disease, in a deal valued up to more than EUR 400 million (\$442 million). [Read More](#)

6. [Novo Nordisk To Expand Insulin Production Facility](#)

Novo Nordisk is investing DKK 400 million (\$59.4 million) in a 500-square meter extension of its insulin production plant in Kalundborg, Denmark. With its 3,400 employees, Novo Nordisk

Kalundborg is a key part of Novo Nordisk's global production. The expansion is expected to be completed at the end of 2018. [Read More](#)

7. [Sanofi, WRAIR Sign Research Pact For Zika Vaccine](#)

Sanofi has formed a research agreement with the Walter Reed Army Institute of Research (WRAIR), a government biomedical research laboratory under the US Department of Defense, for the joint development of a Zika vaccine candidate. The Silver Springs, Maryland-based WRAIR will transfer its vaccine technology for Zika purified inactivated virus (ZPIV) to Sanofi Pasteur, the global vaccines business unit of Sanofi. [Read More](#)

8. [EMA Continues Operations As Usual Despite Brexit](#)

The European Medicines Agency (EMA) issued a statement to assure its procedures and work stream are not now affected by the United Kingdom's exit from the European Union (EU). On June 23, 2016 the UK voted in a public referendum to end its membership in the EU in a move widely known as Brexit. A decision of whether to re-locate the EMA, which is housed in London, is up to EU member states. [Read More](#)

9. [Torrent Pharma Acquires Glochem's API Manufacturing Unit](#)

Torrent Pharma, an India-based pharmaceutical company, has entered a binding agreement to acquire the active pharmaceutical ingredient (API) manufacturing unit in Vizag, India of Hyderabad, India-based Glochem Industries, an API and drug intermediates manufacturer in India. The acquisition also includes some drug master files. [Read More](#)

10. [EC OKs AbbVie's, Biogen's MS Drug Zinbryta](#)

The European Commission has granted marketing authorization to AbbVie's and Biogen's Zinbryta (daclizumab) for treating relapsing forms of multiple sclerosis. Zinbryta is also approved in the United States and is under regulatory review in Switzerland, Canada, and Australia. [Read More](#)

****Upcoming DCAT Event****

[DCAT Announces Its Newest Member Networking Event](#)

Enjoy all that Barcelona has to offer while making valuable industry connections at **DCAT After the Show**, DCAT's newest member networking event held immediately following CPhI Worldwide in Barcelona on Wednesday, October 5, from 6:00 PM to 8:30 PM. Located at the beautiful Casa Llotja de Mar, this venue is just steps away from the Gothic Quarter and Port of Barcelona, offering member company representatives the perfect opportunity to engage with colleagues they may have missed at the show before attending their customer events.

Registration for this event will open July 20, 2016. The reception is \$79.00 USD per person, and includes food and beverage, and transportation from the show to Casa Llotja de Mar, compliments of ACIC Fine Chemicals, Inc. Further event information and available branding opportunities may be found [here](#).

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org